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Abstract
Regulation of gene expression requires transcription factor binding to specific DNA elements, and a large body of work has
focused on the identification of such sequences. However, it is becoming increasingly clear that eukaryotic transcription
factors can exhibit widespread, nonfunctional binding to genomic DNA sites. Conversely, some of these proteins, such as
E2F, can also modulate gene expression by binding to non-consensus elements. E2F comprises a family of transcription
factors that play key roles in a wide variety of cellular functions, including survival, differentiation, activation during tissue
regeneration, metabolism, and proliferation. E2F factors bind to the Erb3-binding protein 1 (EBP1) promoter in live cells. We
now show that E2F binding to the EBP1 promoter occurs through two tandem DNA elements that do not conform to typical
consensus E2F motifs. Exogenously expressed E2F1 activates EBP1 reporters lacking one, but not both sites, suggesting a
degree of redundancy under certain conditions. E2F1 increases the levels of endogenous EBP1 mRNA in breast carcinoma
and other transformed cell lines. In contrast, in non-transformed primary epidermal keratinocytes, E2F, together with the
retinoblastoma family of proteins, appears to be involved in decreasing EBP1 mRNA abundance in response to growth
inhibition by transforming growth factor-b1. Thus, E2F is likely a central coordinator of multiple responses that culminate in
regulation of EBP1 gene expression, and which may vary depending on cell type and context.
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Introduction
The E2F family of transcription factors has frequently been
associated with regulation of cell cycle progression from G1 to S
phase [1,2]. However, additional studies, including genome-wide
analyses, have revealed that E2F factors modulate a plethora of
cellular functions, including DNA replication and repair, apopto-
sis, signal transduction, and metabolism [1,2]. Not surprisingly, an
increasing number of pathologies have been associated with
abnormal E2F expression or activity, ranging from developmental
diseases and cancer to neurodegenerative disorders [3,4].
E2F proteins belong to a class of transcription factors that
appear to predominantly bind proximal promoter regions close to
the transcription start site of target genes [5]. These interactions
can result in stabilization of general transcription machinery and
activation of gene expression, or in transcriptional repression,
depending on E2F interactions with other proteins, or on the
particular E2F member bound to the DNA [6]. Early analysis of
E2F-regulated promoters identified DNA sequences that con-
formed to the consensus 59-TTTSSCGC- 39 (where S is either C
or G) [7]. However, genome-wide analyses have revealed that only
a minority of E2F-bound promoters actually contain this
consensus site [8]. Although the functional significance of most
of these sites remains to be assessed, regulation by E2F upon
binding to a diverse group of sequences, such as 59-
GGGCGGGC-39 and 59-GCTCCAAA-39, has been demonstrat-
ed for the ASK-1, and the carboxylesterase gene promoters,
respectively [8,9,10].
Most high-throughput analyses of putative E2F targets have
been conducted using transformed cell lines. In an effort to
identify novel E2F targets in normal cell types, we undertook a
genome-wide analysis of E2F-bound genes in human epidermal
keratinocytes, using chromatin immunoprecipitation (ChIP)
coupled to CpG island microarray analysis. We found that
E2F1 can bind the ErbB3-binding protein 1 (EBP1) promoter in
live cells [11].
EBP1 is a ubiquitous, cell cycle-regulated protein, which can
suppress growth in certain types of prostate and breast
carcinoma cells, and can regulate sensitivity to Tamoxifen in
certain breast tumors [12]. EBP1 appears to fulfill multiple
diverse biological functions. It can bind DNA, RNA and
proteins, and can modulate transcription, protein translation
and protein stability [13]. The biological effects of EBP1 vary
depending on cell type and context, although the precise
mechanisms for the differential roles and regulation of EBP1 in
different tissues have not been defined. Significantly, EBP1 can
repress E2F transcriptional activity in reporter assays, through its
ability to bind to histone deacetylase 2 and pRB [14], suggesting
PLoS ONE | www.plosone.org 1 November 2010 | Volume 5 | Issue 11 | e13941the possibility of cross-talk between the E2F and EBP1 pathways.
In this report, we have explored how E2F1 regulates the EBP1
promoter, and demonstrate the functional importance of dual
DNA elements in modulating EBP1 transcriptional activation by
E2F proteins.
Results
Identification of EBP1 as an E2F target gene
To determine whether EBP1 is a bona fide E2F target, we first
conducted ChIP experiments using chromatin isolated from
Figure 1. Regulation of the EBP1 promoter by E2F and pRb proteins. (A) Chromatin immunoprecipitation assays were conducted with
antibodies against the indicated proteins and chromatin isolated from exponentially proliferating, unsynchronized cultures of primary epidermal
keratinocytes. The DNA immunoprecipitated was amplified with primers specific to the proximal promoter of the EBP1 gene. Controls included
immunoprecipitation with an irrelevant IgG and amplification with 0.2% of the isolated chromatin, prior to immunoprecipitation (‘Input’’). (B)
Schematic diagram of the human EBP1 promoter fragment isolated and used in reporter assays. The positions relative to the transcription start site
(set to +1) of putative binding sites identified in silico for the indicated transcription factors are shown. (C, D) The firefly luciferase reporter driven by
the EBP1 promoter fragment shown in (B) (2980 Luc) was transiently transfected into primary human keratinocytes, together with vectors encoding
the indicated E2F or pRb family proteins. All samples were cotransfected with a vector encoding Renilla luciferase. EBP1-luciferase activity was
normalized to Renilla luciferase. The results are expressed as the mean +SEM (n=3) relative to normalized luciferase activity in samples transfected
with 2980 Luc together with empty vector not encoding for any E2F or pRb protein (set to 1). * indicates p,0.05 (ANOVA).
doi:10.1371/journal.pone.0013941.g001
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We determined that E2Fs 1, 3, 4, and 5 were capable of binding
this promoter (Fig. 1A). We extended this analysis to the
retinoblastoma family of proteins (pRb, p107 and p130), as they
modulate E2F transcriptional activity, and found that all three
proteins associated with the proximal EBP1 promoter in live
keratinocytes (Fig. 1A), which is consistent with our previous
reports [11].
To begin to examine the functional significance of E2F binding
to the EBP1 promoter, we used polymerase chain reaction (PCR)
to amplify human keratinocyte genomic sequences corresponding
to positions 2980 to +80 (termed 2980 Luc), relative to the
predicted transcription start site. In silico analyses of this fragment
revealed a consensus E2F site centered at position 2374 (Fig. S1).
Two additional sites with about 90% homology to the E2F
consensus were identified, centered at positions 2759 and +3 (Fig.
S1). Putative binding elements for SP1, Ikaros and Heat shock
factor 2 (HSF2) were also localized to positions 2344, 2141 and
244, respectively (Figs. 1B and S1). The EBP1 fragment we
isolated lacks a TATA box, and exhibits promoter activity, as it is
capable of directing expression of a luciferase reporter transfected
into neonatal epidermal human keratinocytes (Fig. 1C), and is
activated about 10-fold by exogenous expression of E2F1, 23 and
25 in these cells (Fig. 1C). We also observed that exogenous E2F
was able to activate this construct 2- and 3-fold, respectively, in
HaCaT cells (an immortalized line established from human adult
keratinocytes) and IMDF dermal fibroblasts [15] (data not shown),
indicating that activation of the EBP1 promoter by E2F is not cell
type-specific. These assays were repeated in the presence of
exogenously expressed pRb, p107 or p130. We found that pRb
significantly decreased EBP1 promoter activity (Fig 1D). These
data show that the EBP1 promoter displays characteristics
consistent with a bona fide, novel E2F target.
Identification of regions modulated by E2F in the EBP1
promoter
To identify functionally important cis-acting elements in the
EBP1 promoter, we generated a series of reporter constructs
containing 59 deletions, and tested them using luciferase reporter
assays (Fig 2A). Deletion of fragments comprising sequences from
2980 to 2450 was without effect on basal promoter activity,
contrasting with the pronounced decrease in transcriptional
activity consequent to loss of the region between 2450 and
2100 (Fig. 2B). To determine the role of this region in E2F-
mediated promoter regulation, we measured reporter activity in
cells cotransfected with vectors encoding E2F1 or E2F3, as
exogenous expression of these two proteins had resulted in
pronounced promoter activation (Fig. 1C). Whereas the 2980,
2650 and 2450 to +80 fragments of the EBP1 promoter were
activated to similar extents by E2F1 or E2F3, transcriptional
activity of the construct containing the region from 2100 to +80
was not significantly altered (Fig 2B). Thus, sequences between
positions 2450 and 2100 are necessary and sufficient for basal
and E2F-enhanced transcription. Consistent with this notion,
exogenous expression of pRb significantly inhibited promoter
activity only in reporters containing the 2450 to 2100 region
(Fig 2C). Additional experiments with promoter fragments
containing mutations in one or both of the sites centered at
positions 2759 and 2374 in the context of 2980 Luc showed that
these alterations had no effect on transcriptional activity (data not
shown). Together, these results indicate that the putative E2F sites
at 2759 and 2374 are dispensable for and/or not involved in
EBP1 promoter activity and regulation by E2F.
To better map the E2F-responsive region in the EBP1
promoter, we generated a second series of constructs containing
successive 70-bp deletions (Fig 3A). Transient transfection of these
constructs in HaCaT cells demonstrated a relatively small decrease
in promoter activity with loss of sequences between 2310 and
2240, and a substantially larger 6-fold reduction with the deletion
of sequences between 2170 and 2100 (Fig 3B). To further
confirm that these sequences fulfilled functions as E2F-regulated
elements, their ability to activate a heterologous minimal promoter
was assessed. We used a modified luciferase reporter containing
the minimal promoter of the Herpes Simplex 1 virus thymidine kinase.
Presence of the 2170-to2100 region just upstream from this
promoter increased about 12-fold its activity (Fig. 3C). Moreover,
exogenous expression of E2F1 induced further activation, as
evidenced by an additional 12-fold increase in reporter activity
(Fig. 3C). We conclude that an important cis-acting region is
located within positions 2170 to2100 of the EBP1 promoter.
Presence of tandem E2F binding sites in the EBP1
promoter
The results described above indicated the presence of E2F
response elements distinct from the putative sites identified in silico.
As no other obvious consensus E2F sites are present in the region
of interest, we conducted gel electropheretic mobility shift assays
(EMSA), using probes corresponding to various segments of this
promoter fragment (Table S1) and in vitro purified recombinant
E2F1, bacterially produced as a GST fusion protein. GST-E2F1
proteins have been widely used to characterize E2F binding to
DNA in vitro [16], and we reasoned that this approach would allow
us to define elements in the EBP1 promoter directly bound by
E2F. Binding of GST-E2F1 was observed with oligonucleotide
probes comprising sequences 2168 to 2130, as well as 2136 to
2100, but not 2155 to 2120 (Fig. 4A), suggesting the presence of
two distinct E2F sites. To identify them, we conducted EMSA
experiments with linker scanning mutant probes, in which GC-
rich regions, known to be preferentially bound by E2F factors,
were individually altered to poly-A stretches (Fig. 4B). Mutation of
a GCGCG element centered at position 2158 in a probe
comprising sequences from 2168 to 2130 abolished GST-E2F1
binding (Fig. 4B, C). Similarly, mutation of a GCGGC sequence
centered at position 2113 abrogated GST-E2F1 binding to a
probe comprising sequences from 2135 to 2100 (Fig. 4B, C). To
confirm that both of these sequences interact with E2F1, we
conducted additional shift assays using longer probes correspond-
ing to positions 2166 to 2104, including mutant probes in which
one or both of the binding sites at 2158 and 2113 were altered
(Fig. 4D). We observed GST-E2F1 binding to probes in which
only one site had been mutated, indicating that binding to one site
does not depend on interactions with the other site. However,
GST-E2F1 binding was abrogated when both sites were absent,
consistent with the notion that tandem bona fide E2F recognition
Figure 2. Mapping of E2F- and pRb-responsive regions in the EBP1 promoter. (A) Schematic of EBP1 promoter constructs tested. Putative
E2F-binding sites at positions 2759 and 2374 are indicated with a star, and the numbers at right indicate the 59-flanking sequences present in each
construct. (B, C) The indicated EBP1 constructs were co-transfected with vectors encoding E2F1, E2F3 or pRb into primary human keratinocytes,
together with a vector encoding Renilla luciferase, used to normalize for transfection efficiency. Normalized luciferase values are expressed as the
mean + SEM (n=3), relative to the basal activity of the 2980 Luc construct (set to 1). * indicates p,0.05 (ANOVA).
doi:10.1371/journal.pone.0013941.g002
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and 2113, relative to the transcription start site. Further, we also
noted that the wild type probe that contained both sites gave rise
to an abundant complex with very low mobility (indicated with an
arrow, Fig. 4D), possibly due to binding of separate E2F1 proteins
to each of the two sites, creating a higher order complex.
The two E2F sites identified do not conform to classical E2F-
binding consensus sequences, such as those found in the DHFR
promoter. To further investigate the interaction between E2F and
the EBP1 sites, we conducted competition EMSA experiments
using other consensus and non-consensus E2F-binding sites. The
presence of a 100-fold molar excess of unlabelled oligonucleotides
corresponding to either the DHFR or the N-myc classical E2F-
binding site abolished the interaction between GST-E2F1 and
both the 2158 and the 2113 EBP1 sites (Fig. 5A and data not
shown). In contrast, competition with unlabelled oligonucleotides
in which the DHFR or N-myc E2F sites had been mutated to poly-A
stretches had no effect on GST-E2F1 binding to the EBP1 probes
(Fig. 5A and data not shown), further confirming the specificity of
the interactions between GST-E2F1 and the EBP1 sites. We next
used the E2F site in the TIMELESS promoter as a model of a non-
consensus E2F site, as its ability to bind E2F has been well
established and characterized [8]. The presence of a 100-fold
molar excess of wild type, but not mutant, TIMELESS promoter
sequences substantially reduced binding of GST-E2F1 to each of
the EBP1 sites (Fig. 5B). Unexpectedly, the same probe showed
very inefficient competition for the DHFR consensus site under the
same conditions (Fig. 5B). Recent analyses of genome-wide E2F
binding have indicated that E2F target genes can exhibit non-
consensus binding sites, which differ from the consensus sequence,
exhibit lower affinity for E2F in vitro, and may be involved in
different modes of E2F binding [8,9]. Although our studies did not
measure relative affinities, they do confirm the specificity of GST-
E2F1 binding to each if the EBP1 elements identified.
Functional role of the tandem E2F sites in the EBP1
promoter
To assess the functional role of the E2F binding sites in EBP1
transcriptional activity, reporter assays were conducted in
asynchronous cultures of HaCaT cells, using constructs based on
the 2980 Luc backbone, as well as 2158 and/or 2113 mutants
with the same alterations shown to abolish GST-E2F1 binding.
The basal activity of the wild type and mutant promoter constructs
in which one of the two sites was intact was comparable. In
contrast, the joint loss of both E2F sites significantly reduced basal
reporter activity (Fig. 5C), suggesting that there may be a certain
degree of redundancy between these two sites under these
conditions. To determine whether these sites are involved in
transcriptional activation by E2F, we conducted similar experi-
ments in the presence of exogenously expressed E2F1. The latter
significantly increased the activity of the wild type, but not the
double mutant promoter (Fig 5C). Unexpectedly, the presence of
exogenous E2F1 did not significantly enhance the activity of EBP1
constructs containing only one wild type E2F site (Fig. 5C). Thus,
both sites appear to be necessary for EBP1 promoter activation
under conditions in which E2F1 is overexpressed. Regardless, our
data show that the EBP1 promoter contains two functional-
ly important sites bound and regulated by E2F1. These sites
appear to exhibit a certain degree of redundancy under some
circumstances.
Regulation of endogenous EBP1 expression by E2F
To assess the modulation by E2F of endogenous EBP1
expression, we transiently transfected MCF-7 and HEK-293 cells
with vectors encoding E2F1, and measured EBP1 mRNA
abundance 24 h after transfection by quantitative real-time
PCR. These two cell lines offer the advantage of transfecting at
very high efficiency, providing optimal conditions to detect
changes in endogenous EBP1 gene expression in response to
transiently transfected E2F1-encoding vectors. In these experi-
ments, the presence of exogenous E2F1 resulted in a significant, 2-
fold increase in EBP1 mRNA in both cell types (Fig. 6A),
demonstrating that E2F can upregulate the expression of this gene
in different transformed cell types.
In non-transformed cells, pRb forms complexes with E2F and
inhibits transcription of various targets, including c-myc, cdc25A
and telomerase, in response to physiological signals, such as
transforming growth factor-b1 (TGF-b1) stimulation [17,18,19].
We previously determined that TGF-b1 treatment of primary
epidermal keratinocytes results in changes in the pattern of E2F
protein binding to the EBP1 gene [11]. Hence, we measured the
effect of TGF-b1 treatment of these cells on EBP1 mRNA
abundance, and determined that the latter decreased by about 2-
fold in the presence of this growth factor (Fig. 6B). To investigate if
such decrease was due to transcriptional repression, we measured
the effect of TGF-b1 treatment on the activity of 2980 Luc. The
presence of this growth factor reduced reporter activity by about 2-
fold (Fig. 6C). To examine if pRb is involved in TGF-b1
repression of EBP1 promoter activity, we transiently transfected
keratinocytes with the 2980 Luc reporter, followed by treatment
with recombinant adenoviruses encoding either b-galactosidase or
the E7 protein encoded by human papilloma virus (HPV) type 16.
The E7 protein promotes pRb degradation in keratinocytes, thus
allowing activation of E2F targets [20]. Significantly, adenovirus-
induced expression of E7 abolished TGF-b1 repression of EBP1
promoter activity, giving rise to luciferase values indistinguishable
from those in untreated cells (Fig. 6C). Together, these
observations are consistent with a model in which E2F factors
are likely important components in the regulation of EBP1
expression in a variety of cell types and conditions.
Discussion
The transcriptional regulation of gene expression plays crucial
roles in development and homeostasis of all living organisms.
Indeed, alterations in transcription factor activity have been
directly linked to hundreds of human diseases [21]. As a result, a
large body of work has focused on identifying transcription factor
targets. We have combined our previous genome-wide analyses
[11] with more in-depth functional studies, identifying the EBP1
gene as a bona fide E2F target. Our studies have defined a
mechanism of regulation of EBP1 promoter activity that involves
two tandem E2F-binding cis elements located in the proximal
Figure 3. Identification of the E2F response element in the EBP1 promoter. (A) Schematic of EBP1 promoter constructs tested. The in silico
identified E2F-binding site at position 2374 is indicated with a star, and the numbers at right indicate the 59-flanking sequences present in each
construct. (B, C) The indicated constructs were transiently transfected together with a plasmid encoding Renilla luciferase, used to normalize for
transfection efficiency. Normalized luciferase values are expressed as the mean + SEM (n=3), relative to the basal activity of the 2980 Luc construct
(panel B) or the TK-81 vector (panel C), set to 1. * indicates p,0.05 (ANOVA). All luciferase values were significantly different from background activity
obtained with the empty vector PXP2.
doi:10.1371/journal.pone.0013941.g003
E2F Regulates EBP1 Expression
PLoS ONE | www.plosone.org 6 November 2010 | Volume 5 | Issue 11 | e13941Figure 4. E2F binds to non-consensus tandem sequences in the EBP1 promoter. (A) Purified recombinant GST or GST-E2F1 was allowed to
bind to [
32P]-labeled, double-stranded oligonucleotide probes corresponding to the following sequences in the EBP1 promoter: 2168 to 2130
(2168), 2155 to 2120 (2155) and 2136 to 2100 (2136). Protein-DNA complexes were resolved by non-denaturing gel electrophoresis. The lower
and the highest mobility signals in the gel correspond, respectively, to GST-E2F1-containing complexes and the free probe. A reaction with a probe
corresponding to the E2F- binding site in the dihydrofolate reductase promoter (DHFR) was included as positive control. (B) Sequences of wild type
and mutant probes used in EMSA experiments. Numbers on the left indicate the identification number for each probe. Bold, underlined A residues
E2F Regulates EBP1 Expression
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these two sites are conserved in the EBP1 promoters of Homo
sapiens, Mus musculus, Rattus norvegicus, Bos Taurus and Mucaca mulatta.
Both sites differ from the elements we originally identified in silico.
This is consistent with the reported large fraction of E2F-bound
elements in the human genome which do not conform to classical
consensus E2F-binding sites, underscoring the limitations of in silico
analysis, as well as the importance of functional analysis of
individual targets. Notably, we found that, under steady-state
conditions, the consensus E2F site found in the DHFR promoter
competed more effectively for binding to recombinant E2F1 than
the non-consensus elements in the EBP1 or the TIMELESS
promoter. This observation is consistent with previous studies
demonstrating that the consensus E2F motif is preferred in vitro
[22]. E2F binding to DNA in vivo is modulated by multiple factors
in addition to particular motifs. They include adjacent DNA
elements and/or post-translational modifications of E2F protein,
which may increase binding affinity, as well as chromatin
modifications that would increase accessibility to the DNA and
E2F interactions with other transcription factors, which allow the
formation of more stable, cooperative multimeric complexes [8].
Unresolved issues for future studies include whether binding of
other transcription factors to the EBP1 promoter aid in the
recruitment of E2F proteins.
A number of E2F target genes exhibit a complex promoter
structure with two E2F sites, including the E2F1, the p107 and, as
we showed, the EBP1 promoter. Each site can contribute
differently to control of the target gene. For example, both
activation and repression of p107 expression or p107 reporter
plasmids are mainly, but not exclusively, regulated through the
distal E2F site [23]. Further, it has been shown that the two sites in
the p107 gene fulfill distinct roles, depending on the cell type and
biological context. In contrast, neither of the two sites identified in
the EBP1 promoter appears to predominate over the other,
although loss of both sites resulted in substantial loss of basal and
E2F1-induced promoter activity. These observations would
suggest that there might be some functional redundancy between
the two sites, at least in the framework of reporter assays. Whether
this is also the case in the context of native chromatin, and
whether each of these sites plays differential roles in activation vs.
repression by endogenous E2F proteins is an area of future
important research.
EBP1 is a ubiquitous protein with multiple, complex functions
involved in transcription and translation, cell proliferation and
survival [24,25,26,27]. The mouse orthologue of EBP1 was first
identified by virtue of its regulation through the cell cycle. Its
expression increases at the G1/S boundary, and is greatly reduced
during S phase or in quiescent cells [28]. This pattern of expression
is analogous to that of a large number of E2F-regulated genes. Early
work characterized EBP1 as a growth suppressor of prostate and
breast carcinoma cell lines that express high Erb2/3 levels [13].
Paradoxically, mice with targeted inactivation of Ebp1 exhibit
reduced overall growth, and cultured Ebp1-null mouse embryo
fibroblasts fail to proliferate normally [27], further demonstrating
that EBP1 functions are cell type- and context-specific.
Given the pleiotropic nature of EBP1 activities, and the
multiplicity of mechanisms that operate in transcriptional
regulation by E2F, the biological consequences of E2F-mediated
EBP1 expression are likely to be very complex. For example, in
some breast tumors, there is a loss of E2F1 expression and that of
its targets, such as EBP1 and apoptosis-inducing genes [29]. These
alterations are thought to constitute a mechanism of growth
advantage in these tumor types. We have shown that in MCF-7
breast carcinoma cells, exogenous E2F1 expression increased
EBP1 transcript levels. These cells belong to a class of breast
tumors that express wild type pRb and p53, and in which
enhanced growth occurs, at least in part, through ErbB2/3-
dependent mechanisms [29]. Exogenous E2F1 expression in
MCF-7 cells also induces growth arrest, without adverse effects
on cell viability [29], although the contribution of increased EBP1
in these effects of E2F1 remains unexplored. Thus, modulation of
E2F1 activity and/or levels may selectively target certain types of
tumors to apoptosis and/or growth arrest, sparing normal cells.
Our studies also suggest the possibility that the consequences of
E2F regulation of EBP1 expression may be different in non-
transformed cells. For example, in keratinocytes, the pRb family
proteins and E2F1 likely participate in the regulation of EBP1
under certain conditions. In asynchronously growing keratinocyte
populations, binding of E2F1, -3, -4 and 5, as well as all pRb
family proteins has been detected. TGF-b1 treatment of these cells
is associated with loss of detectable E2F1, p107 and p130 binding
to the EBP1 promoter [11], and a concomitant decrease in EBP1
mRNA levels (Fig. 6). The inhibitory effects of TGF-b1o nEBP1
promoter activity are abrogated by the HPV-16 E7 protein.
Although E7 targets all pRb family proteins, its effects on EBP1
expression may be mediated to a large extent by abolishing pRb-
mediated transcriptional repression, given that p107 and p130 do
not appear to bind to the promoter in the presence of this growth
factor. Based on these observations, we propose a model of EBP1
transcriptional regulation in keratinocytes in which E2F1 activates
EBP1 transcription in exponentially proliferating cells, whereas
reversible growth inhibition and entry into quiescence induced by
TGF-b1 induce transcriptional repression mediated, at least in
part, by pRb complexes containing other E2F proteins, such as
E2F3 and/or E2F4.
In summary, we have demonstrated the presence of tandem
non-consensus E2F-binding elements in the EBP1 promoter,
which play key roles in its transcriptional activity. We have also
shown that E2F1 can activate EPB1 expression in a variety of cell
types, although the ultimate biological consequences of this
regulation are likely to differ between cell types and/or context.
A key area for future research will be the investigation of the
relative roles that each of the two E2F-binding sites play in
transcriptional activation and repression in the context of
endogenous EBP1 gene expression. This will provide crucial
insights of how E2F target gene regulation is achieved from
genomic information.
Materials and Methods
Ethics statement
Primary epidermal human keratinocytes were isolated from
neonatal foreskins from anonymous donors. Written informed
consent from the donors’ guardians was obtained to process the
indicate mutations introduced in the probes. (C) EMSA using GST or GST-E2F1 together with a [
32P]-labeled, double-stranded oligonucleotide probe
corresponding to the DHFR E2F-binding site, or one of the sequences shown in panel B, as indicated. (D) EMSA using GST or GST-E2F1 together with a
[
32P]-labeled, double-stranded oligonucleotide probe corresponding to EBP1 promoter sequences from 2166 to 2104. The probes contained either
wild type sequences (wt), or mutants in the GC-rich regions centered at positions 2158, 2113 (indicated with *), or both. The arrow indicates a lower
mobility complex abundant in the binding reaction containing wild type probe. The highest mobility signals correspond to the free probe.
doi:10.1371/journal.pone.0013941.g004
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undertaken with approval from The University of Western
Ontario Research Ethics Board for Health Sciences Research
Involving Human Subjects (Protocol No. 10480E).
Cell culture, transient transfections and adenovirus
infections
Primary epidermal human keratinocytes were isolated from
neonatal foreskins, and were cultured as described [11], and used
between passages 3–5. IMDF mouse dermal fibroblasts [15],
HaCaT, MCF-7 and HEK 293 cells were cultured in DMEM
supplemented with 4% fetal bovine serum (FBS). All cells were
transiently transfected as described [30]. For experiments using
adenovirus-mediated E7 expression, triplicate human keratinocyte
cultures were transfected with luciferase reporters for 5 h, followed
by infection for 3 h with recombinant adenoviruses encoding
green fluorescent protein, together with either the E7 protein from
HPV 16 [31] or b-galactosidase [32] as a control. A multiplicity of
infection of 50–75 was used. Sixteen hours later, cells were treated
with vehicle or with TGF-b1 (10 ng/ml) for 24 h. Cell lysates were
prepared and luciferase activity was assayed as described below.
Plasmids
Fragments of the 59- flanking sequences of the human EBP1
gene were obtained by PCR amplification using primers shown in
Table S1. Amplicons were cloned into the promoterless firefly
luciferase vector PXP2 [33]. The base construct containing 980 bp
of 59-flanking sequences (termed 2980 Luc) was used as a
template to generate additional promoter fragments by PCR. All
promoter sequences generated were verified by dideoxy sequenc-
ing. EBP1 constructs containing mutations at positions 2158 and
2113 were generated using a Quikchange Mutagenesis kit
(Stratagene), following the manufacturer’s instructions. To gener-
ate heterologous promoter constructs, a fragment containing
sequences corresponding to positions 2170 to 2100 was cloned
into pTK81, a vector identical to PXP2, but containing a minimal
Herpes Simplex thymidine kinase promoter preceding the luciferase
encoding region [33].
Chromatin Immunoprecipitation (ChIP)
For ChIP assays, chromatin was isolated from exponentially
proliferating, unsynchronized human keratinocytes, as described
[11]. Isolated chromatin was sonicated to produce 500–2000 bp
fragments for immunoprecipitation with one of the following
antibodies: E2F1 (Upstate, 05-376), E2F3 (Santa Cruz, SC-878),
E2F4 (Santa Cruz, SC-366), E2F5 (Santa Cruz, SC-999), pRb
(BD Pharmingen, 554136), p107 (Santa Cruz, SC-318X), and
p130 (Santa Cruz, SC-317X). Following reversal of cross-linking,
the DNA was purified using a polymerase chain reaction (PCR)
clean-up kit (Qiagen). DNA samples were amplified by PCR,
generating amplicons corresponding to positions 2431 to 2143,
relative to the transcription start site, with the following primers:
59-CGGTGCGGCCTCCACTCTACTCCAC-39 and 59-GCGT
GCCTCTCGCGCTCCTAAG-39
Electrophoretic mobility shift assays (EMSA)
Electrophoretic mobility shift assays were conducted as
described [34], except that reactions contained 24 ng/mlo fa
double stranded oligonucleotide corresponding to a mutant E2F
binding site of the adenovirus E2 promoter incapable of binding to
E2F in place of a mutant DHFR oligonucleotide to eliminate non-
specific binding to the probe. For these assays, 1.8 mg of purified
GST or GST-E2F1 was used per binding reaction. Competition
assays contained 100-fold molar excess of appropriate unlabeled
oligonucleotide.
Luciferase reporter assays
Cells cultured in 12-well plates were transfected with either
1 mg/well of luciferase reporter, or 250 ng of luciferase reporter
and 1 mg of a vector encoding V5-tagged E2F1 (or pcDNA3.1
plasmid as a control) per well. In all cases, 2 ng of phRL-CMV
plasmid (Promega) encoding Renilla luciferase was included to
normalize for transfection efficiency. Transfections were conduct-
ed as described [30]. Cells were harvested 24 h after transfection,
and luciferase activity in cell lysates was measured with Dual
Luciferase Assay Kits (Promega) as per manufacturer’s protocol.
Reporter activity was normalized to Renilla luciferase values. All
treatments were done in triplicate, and the data were analyzed by
one-way ANOVA with Bonferroni post-hoc test, except in
experiments in which E2F-encoding vectors were cotransfected,
for which two-way ANOVA with no repeated measures was used.
Significance was set at P,0.05.
RNA analysis
RNA from human keratinocytes (untreated or treated with
TGF-b1 for 48 hours) was isolated using the guanidinium
isothiocyanate method [35]. 20 mg of each RNA sample was
fractionated on a 1.2% agarose gel containing 1% formaldehyde,
and transferred onto a Hybond-N membrane (Amersham
Biosciences). The resulting blots were hybridized for 20 hours at
42uC in UltraHyb solution (Ambion) to [
32P]-labelled DNA
probes. The probes for human EBP1 and 18S rRNA were
generated by PCR amplification of human keratinocyte cDNA.
EBP1 mRNA levels were normalized to those of 18S rRNA.
For analysis of E2F1 effects on EBP1 expression in MCF-7 and
HEK-293 cells, cultures were transfected with a plasmid encoding
V5-tagged E2F1, or with empty vector control. Twenty-four hours
after transfection, total RNA was isolated using RNeasy Mini kits
(Qiagen), as per manufacturer’s protocol. Following verification of
their integrity, RNA samples were reverse transcribed with
Superscript II (Invitrogen), following manufacturer’s instructions.
The primers used to determine relative transcript abundance were
EBP1 and, to normalize, RPL 22, RPL 27 and RPL 30 [36]
(Table S1). Triplicate cDNA samples were amplified for 40 cycles
Figure 5. Regulation of the EBP1 promoter by tandem E2F-binding sites. (A, B) Purified recombinant GST or GST-E2F1 was allowed to bind to
[
32P]-labeled, double-stranded oligonucleotide probes corresponding to the DHFR E2F-binding site, or EBP1 promoter sequences containing the E2F
binding site centered at position 2158 or at position 2113. Binding reactions were conducted in the presence of a 100-fold molar excess of
unlabelled oligonucleotides corresponding to the wild type (wt) or mutant (mut) DHFR E2F-binding site (panel A), or wild type (wt) or mutant (mut)
E2F-binding site in the TIMELESS promoter (panel B). Protein-DNA complexes were resolved by non-denaturing gel electrophoresis. GST-E2F1-
containing complexes are shown. (C) Luciferase reporter constructs corresponding to positions 2980 to +80 of the EBP1 promoter were transiently
transfected into HaCaT cells, together with a vector or a plasmid encoding E2F1. The EBP1 constructs used were either wild type (wt), or mutants in
which the E2F-binding sites centered at positions 2158 (2158*) and/or 2113 (2113*) were mutated. EBP1-directed luciferase activities were
normalized to Renilla luciferase, and expressed relative to the activity of the wild type 2980 Luc construct, which was set to 1. The results are
expressed as the average + SEM (n=3). * indicates p,0.05 (ANOVA) relative to 2980 Luc in the absence of exogenous E2F1.
doi:10.1371/journal.pone.0013941.g005
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PLoS ONE | www.plosone.org 10 November 2010 | Volume 5 | Issue 11 | e13941Figure 6. Regulation of EBP1 gene expression by E2F/pRb. (A) Exponentially proliferating MCF-7 or HEK-293 cells were transiently transfected
with an empty vector or an E2F1-encoding plasmid. Twenty-four hours after transfection, RNA was isolated from the cultures, reverse-transcribed and
subjected to real-time PCR analysis using EBP1-specific primers. The data are normalized to control RPL 20, RPL 27 and RPL 30 RNA, and are expressed
relative to vector-transfected cells, set to 1. Results are expressed as mean + SEM (n=3). * indicates p,0.05 (Student’s t test). (B) Triplicate cultures of
exponentially proliferating, unsynchronized primary epidermal human keratinocytes were treated for 48 h in the presence or absence of TGF-b1
(10 ng/ml). Total RNA was isolated, fractionated on agarose gels and transferred to a membrane. Northern blot analysis was conducted with [
32P]-
labelled probes corresponding to the EBP1 mRNA, or to 18S rRNA (as a loading control). The results are expressed as the mean + SEM of normalized
EBP1 mRNA levels, with abundance in untreated cells set to 1 (n=3). * indicates p,0.05 (Student’s t test). (C) Primary human epidermal keratinocytes
were co-transfected with 2980 Luc and a vector encoding Renilla luciferase. Five hours after transfection, the cells were incubated with recombinant
adenoviruses encoding b-galactosidase (b-gal) or HPV-16 E7 for 3 h. Following a 16-h incubation in normal growth medium, the cells were cultured
for an additional 24-h period in the presence or absence of TGF-b1 (10 ng/ml). Luciferase activity in keratinocyte lysates was measured and
normalized to Renilla luciferase. The results are expressed as the mean + SEM (n=3), with luciferase activity in uninfected cells cultured without TGF-
b1 set to 1. * indicates p,0.05 (ANOVA).
doi:10.1371/journal.pone.0013941.g006
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PLoS ONE | www.plosone.org 11 November 2010 | Volume 5 | Issue 11 | e13941(95uC for 15 sec; 50uC for 1 min) and Ct values were obtained.
The results were analyzed using SDS 2.3 software (Applied
Biosystems Inc.). Relative EBP1 transcript levels were calculated
using the DDCt method.
Supporting Information
Figure S1 Sequence of the human EBP1 promoter. Numbers on
the right indicate positions relative to the predicted transcription
start site (set to +1, indicated by the arrow). Consensus binding
motifs for the indicated transcription factors predicted in silico are
highlighted and underlined.
Found at: doi:10.1371/journal.pone.0013941.s001 (0.03 MB
DOC)
Table S1 Primer sequences.
Found at: doi:10.1371/journal.pone.0013941.s002 (0.06 MB
DOC)
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